阿司匹林联合氯吡格雷是冠状动脉支架植入术后常规的抗血小板治疗方案。然而,近年来的研究显示接受上述治疗的部分患者血小板的抑制率较低,即氯吡格雷抵抗,与冠脉支架植入术后支架内血栓事件的发生存在因果关系。而导致氯吡格雷抵抗的原因复杂,研究表明CYP2C19基因多态性与其明显相关,对高危人群进行CYP2C19基因多态性检测有利于识别氯吡格雷抵抗,并及时增加氯吡格雷剂量或更换新型血小板P2Y12受体拮抗剂,可降低术后支架内血栓的发生。 Aspirin combined with clopidogrel is a routine antiplatelet regimen after coronary stenting. However, recent studies have shown that in some patients undergoing the above treatment, the platelet inhibition rate is low, that is, clopidogrel resistance has a causal relationship with the occurrence of stent thrombosis after coronary stent implantation. The cause of clopidogrel resistance is complex. Studies have shown that CYP2C19 gene polymorphism is significantly associated with CYP2C19 polymorphism detection of high-risk groups is conducive to the identification of clopidogrel resistance and timely increase in the dose of clopidogrel or replacement of new platelets P2Y12 receptor antagonist, can reduce postoperative stent thrombosis.